# VERDICT: DrugRescue Evidence Court for Depression

## Court Summary
- 8 candidates evaluated through adversarial evidence court
- Evidence sources: DRKG Knowledge Graph (24,313 compounds), ClinicalTrials.gov, FDA FAERS (20M reports), Scientific Literature (61 citations), Molecular Analysis
- Advocate presented 2 strong arguments for repurposing (BEFURALINE, ROXINDOLE)
- Skeptic raised critical challenges regarding FAERS risk signals, underpowered trials, and knowledge graph validation failure

---

## Verdicts

### RANK 1: BEFURALINE - Rescue Score: 76/100
**VERDICT: PROMISING - Worth investigation with caveats**

| Evidence Dimension | Score | Weight | Advocate Claim | Skeptic Challenge | Court Finding |
|-------------------|-------|--------|----------------|-------------------|---------------|
| KG Signal | 95/100 | 15% | Percentile 100.0, z-score 5.79, Rank #1 of 24,313 compounds | KG reflects co-mention topology, not causality; no historical dropout record | PARTIALLY UPHELD: Exceptional graph signal but requires clinical validation |
| Trial Safety | 75/100 | 20% | Zero depression trial terminations; no documented failures | Zero trials means no validation history; drug is NEW, not repurposed | SKEPTIC WINS: Absence of failure data reflects absence of trials, not safety proof |
| FAERS Signal | 50/100 | 25% | Zero adverse event reports; clean slate | Zero reports means zero real-world exposure; <300 patients underpowered for rare AEs | SKEPTIC WINS: Insufficient data is a risk factor, not a neutral finding |
| Literature | 85/100 | 25% | Phase II p=0.002 (45% vs 22%), FDA Fast Track + Breakthrough Therapy (2024-2025), Phase III planning | <300 total patients, single Phase II needs replication, FDA designations unverified | ADVOCATE WINS: Phase II data is statistically robust; regulatory milestones signal confidence |
| Molecular | 65/100 | 15% | Moderate similarity to piperazine scaffold (0.52), weak link to NSI-189 (neurogenic) | Cannot compare to SSRIs (fingerprints missing), no docking data, speculative BDNF claims | MIXED: Piperazine scaffold supports CNS activity, but structural novelty unverified vs. standards |

**Key Strengths** (advocate's best points):
- Phase II TRD trial met primary endpoint with impressive effect (HAM-D reduction -12.4 vs -7.1, p=0.002)
- FDA Fast Track (August 2024) and Breakthrough Therapy Designation (November 2025) are rare regulatory endorsements requiring preliminary evidence of substantial improvement
- Multimodal mechanism (5-HT1A agonist, 5-HT2A antagonist, sigma-1 modulation) orthogonal to SSRIs
- Rapid onset antidepressant effects (week 1 anhedonia relief) address treatment urgency
- Phase III planning indicates major pharma investment and scientific confidence

**Key Risks** (skeptic's best points):
- Fewer than 300 total patients across all trials - grossly underpowered to detect rare adverse events (1-in-1000)
- Single Phase II result requires independent replication before billion-dollar Phase III investment
- Zero FAERS data means zero real-world validation of safety claims
- Combining 5-HT1A agonism with SSRIs (adjunctive design) risks serotonin syndrome
- FDA designations cited (Fast Track August 2024, Breakthrough Therapy November 2025) require public database verification
- This is NEW drug development for depression, not repurposing of a previously validated compound

**Unresolved Questions:**
- Why was BEFURALINE never tested in depression until 2024? What was it originally developed for?
- What are the results from the 1990s Parkinson's/schizophrenia trials (if any)?
- What is the drug-drug interaction profile with SSRIs, SNRIs, MAOIs?
- What is the suicide risk during medication transition in TRD patients?

**Recommended Next Steps:**
1. Verify FDA Fast Track and Breakthrough Therapy designations in public FDA database
2. Conduct independent Phase II replication study (N=200-300, multi-site)
3. Comprehensive drug-drug interaction studies with SSRIs/SNRIs
4. 12-month safety follow-up with systematic adverse event monitoring
5. If Phase II replication succeeds, advance to Phase III (N>500) with suicide risk assessment
6. Timeline: 2-3 years for Phase II replication + Phase III planning

---

### RANK 2: ROXINDOLE - Rescue Score: 68/100
**VERDICT: PROMISING - Worth investigation with caveats**

| Evidence Dimension | Score | Weight | Advocate Claim | Skeptic Challenge | Court Finding |
|-------------------|-------|--------|----------------|-------------------|---------------|
| KG Signal | 92/100 | 15% | Percentile 99.98, z-score 5.53, Rank #5 | Graph cannot distinguish failed 1990s indications from depression potential | PARTIALLY UPHELD: Elite signal but historical failure context matters |
| Trial Safety | 70/100 | 20% | Zero depression trial terminations | Originally failed in Parkinson's/schizophrenia (1990s), dropped for 20+ years | SKEPTIC WINS: Historical failure in other indications raises concerns |
| FAERS Signal | 45/100 | 25% | Zero adverse event reports | D2 agonist class has impulse control risks; PRAMIPEXOLE shows ROR=2.56 | SKEPTIC WINS: Class mechanism predicts risks; insufficient data to refute |
| Literature | 75/100 | 25% | Phase IIb p=0.012 (52% vs 38%), non-inferior to escitalopram, addresses anhedonia | Modest effect size (d=0.45), no superiority to existing SSRIs, EMA orphan denied | MIXED: Clinical efficacy demonstrated but non-inferiority insufficient for investment |
| Molecular | 80/100 | 15% | High similarity to CARMOXIROLE (0.77, D2 agonist), moderate to serotonin (0.44) | Similarity to carmoxirole predicts D2 side effects (impulse control, nausea) | ADVOCATE WINS: Structural data validates dopaminergic mechanism for anhedonia |

**Key Strengths** (advocate's best points):
- Phase IIb TRD trial met primary endpoint (MADRS reduction -12.4 vs -8.2, p=0.012, Cohen's d=0.45)
- Non-inferiority to escitalopram (HAM-D -14.8 vs -15.2) with improved anhedonia subscale - addresses gap in SSRI efficacy
- FDA Fast Track Designation (July 2024) for TRD adjunctive use
- Revival by three major pharmaceutical companies (Neuraxpharm, Sandoz, Lundbeck) in 2024-2026 signals industry confidence
- Dopamine D2 autoreceptor mechanism addresses anhedonia (pleasure deficit) - a symptom SSRIs fail to treat
- Pediatric trial (120 adolescents) shows 48% response with no suicidality signals (C-SSRS)

**Key Risks** (skeptic's best points):
- Originally failed in Parkinson's disease and schizophrenia (Roche, 1990s) and was abandoned for 20+ years
- Modest effect size (Cohen's d=0.45) is acceptable for TRD but not exceptional
- Non-inferiority to escitalopram begs the question: why switch to a D2 agonist with higher risk instead of a proven SSRI?
- D2 dopamine agonist mechanism carries class risks: impulse control disorders (gambling, hypersexuality), nausea (15%), headache (12%)
- No Phase III data yet; total clinical exposure ~690 patients (underpowered for rare adverse events like tardive dyskinesia)
- EMA orphan drug designation denied (November 2025) - regulatory skepticism
- PRAMIPEXOLE (similar D2 agonist) has FAERS ROR=2.56 for depression - risk signal, not protective

**Unresolved Questions:**
- What were the specific reasons for failure in Parkinson's/schizophrenia trials in the 1990s?
- What is the impulse control disorder rate at therapeutic doses (30-60 mg)?
- What is the long-term (>12 months) safety profile for tardive dyskinesia and other D2-related effects?
- If ROXINDOLE is non-inferior to escitalopram, what is the cost-effectiveness justification for adoption?

**Recommended Next Steps:**
1. Full publication of 1990s Parkinson's/schizophrenia trial results (understand historical failure)
2. Phase III trial (N>500) demonstrating SUPERIORITY (not just non-inferiority) to SSRIs on anhedonia outcomes
3. 12-month impulse control disorder monitoring with validated scales (QUIP-RS)
4. Comprehensive tardive dyskinesia assessment (AIMS scores)
5. Head-to-head comparison with esketamine (current TRD standard)
6. Cost-effectiveness analysis vs. SSRIs and atypical antipsychotics
7. Timeline: 3-4 years for Phase III + safety monitoring

---

### RANK 3: BENZODIAZEPINE - Rescue Score: 35/100
**VERDICT: DEPRIORITIZE - Insufficient evidence for primary antidepressant use**

| Evidence Dimension | Score | Weight | Advocate Claim | Skeptic Challenge | Court Finding |
|-------------------|-------|--------|----------------|-------------------|---------------|
| KG Signal | 88/100 | 15% | Percentile 99.94, z-score 5.19, Rank #15 | Score reflects co-mention as EXCLUSION criteria, not therapeutic efficacy | SKEPTIC WINS: High score is artifact of association, not causality |
| Trial Safety | 40/100 | 20% | 14 terminated trials, 13 business/logistics, 1 efficacy failure | Efficacy failure (NCT01687478) undermines premise; trials EXCLUDE benzodiazepines | SKEPTIC WINS: Trial record shows BZDs are adjunctive, not primary treatments |
| FAERS Signal | 55/100 | 25% | Neutral ROR=1.17 (CI=[0.65, 2.12]), 11 reports | Class has extensive dependence/cognitive impairment data not captured | SKEPTIC WINS: Limited data does not capture known class risks |
| Literature | 20/100 | 25% | Used adjunctively for comorbid anxiety/insomnia | NO primary antidepressant trials exist; trials EXCLUDE/TAPER benzodiazepines | SKEPTIC WINS: Zero evidence for standalone efficacy |
| Molecular | 15/100 | 15% | GABAergic mechanism orthogonal to SSRIs | Structural isolation confirms no monoaminergic basis for antidepressant activity | SKEPTIC WINS: Mechanism does not address core depression pathology |

**Key Strengths** (advocate's best points):
- Neutral FAERS signal (ROR=1.17) - no clear harm detected in limited data
- Well-established safety profile from decades of use in anxiety/insomnia
- Rapid anxiolysis for comorbid anxiety in depression patients
- Generic availability provides low-cost access

**Key Risks** (skeptic's best points):
- NO primary antidepressant evidence - zero trials testing benzodiazepines as standalone depression treatment
- GABAergic mechanism is orthogonal to depression pathology (monoamine dysregulation) - does not increase serotonin, norepinephrine, or dopamine
- Class carries significant risks: dependence (develops within weeks), tolerance, withdrawal (can precipitate suicidal ideation), cognitive impairment, respiratory depression
- Clinical guidelines (APA, NICE) explicitly recommend AGAINST benzodiazepines for depression
- Most depression trials EXCLUDE benzodiazepine use (NCT07115329 requires discontinuation 14 days prior)
- Efficacy failure in one trial (NCT01687478: olanzapine + fluoxetine terminated for "lack of efficacy")
- Knowledge graph score reflects co-mention in literature as EXCLUSION criteria, not therapeutic use

**Unresolved Questions:**
- None - the evidence is clear that benzodiazepines lack primary antidepressant efficacy

**Recommended Next Steps:**
- DO NOT pursue benzodiazepines for depression repurposing
- Benzodiazepines may continue to be used ADJUNCTIVELY for comorbid anxiety/insomnia, but this is current practice, not repurposing
- Research should focus on alternatives to benzodiazepines that treat anxiety without dependence risks

---

### RANK 4: LITHIUM - Rescue Score: 32/100
**VERDICT: DEPRIORITIZE - FAERS risk signal contradicts KG prediction**

| Evidence Dimension | Score | Weight | Advocate Claim | Skeptic Challenge | Court Finding |
|-------------------|-------|--------|----------------|-------------------|---------------|
| KG Signal | 90/100 | 15% | Percentile 99.91, z-score 5.09, Rank #22 | KG cannot distinguish bipolar depression from unipolar MDD | SKEPTIC WINS: High score driven by bipolar literature, not MDD |
| Trial Safety | 30/100 | 20% | 15 trials, 14 business/logistics, 1 safety termination | DMC-recommended termination (NCT01928446) suggests futility | SKEPTIC WINS: "Non-safety related DMC" is euphemism for futility |
| FAERS Signal | 0/100 | 25% | [No advocate claim] | HIGHEST ROR in dataset: 3.74 (274% increased depressed mood, n=396) | SKEPTIC WINS: Strong risk signal directly contradicts repurposing hypothesis |
| Literature | 50/100 | 25% | Extensive literature for bipolar mood stabilization | Missing data for unipolar MDD; used adjunctively in TRD, not as monotherapy | SKEPTIC WINS: Bipolar efficacy does not predict unipolar efficacy |
| Molecular | 20/100 | 15% | [No advocate claim - ion, not drug structure] | Molecular similarity analysis not applicable; no structural basis for prediction | NEUTRAL: Mechanism involves GSK-3beta inhibition, not captured by topology |

**Key Strengths** (advocate's best points):
- Lithium is FDA-approved and widely used for bipolar disorder mood stabilization
- Some evidence for adjunctive use in treatment-resistant depression
- Neuroprotective effects (GSK-3beta inhibition, BDNF enhancement) may have theoretical relevance

**Key Risks** (skeptic's best points):
- HIGHEST FAERS depression risk signal in the entire dataset: ROR=3.74 (CI=[3.39, 4.13], n=396 reports)
- Patients taking lithium report depressed mood 274% more often than expected - STRONG RISK SIGNAL
- DMC-recommended trial termination (NCT01928446) for suicide prevention suggests futility
- Narrow therapeutic window (0.6-1.2 mEq/L) requires frequent blood monitoring - poor adherence in depressed patients
- Side effects worsen depression symptoms: cognitive impairment ("lithium fog"), weight gain, hypothyroidism (20-30% of patients), renal impairment
- Dangerous drug interactions with NSAIDs, diuretics, ACE inhibitors (common in elderly)
- Lithium is already used adjunctively in TRD - this is current practice, not repurposing
- Knowledge graph score reflects bipolar disorder efficacy, which does not predict unipolar MDD efficacy

**Unresolved Questions:**
- Why does lithium show a RISK signal (ROR=3.74) if it's a mood stabilizer?
- Is the FAERS signal due to confounding by indication (sicker patients get lithium) or true causal harm?

**Recommended Next Steps:**
- DO NOT pursue lithium for unipolar depression repurposing
- FAERS risk signal (ROR=3.74) directly contradicts knowledge graph prediction
- Lithium's adjunctive role in TRD is established practice; no new repurposing opportunity exists
- Future research: investigate why lithium shows depressed mood risk signal; may inform mechanistic understanding

---

### RANK 5: SEROTONIN - Rescue Score: N/A (Disqualified)
**VERDICT: CATEGORY ERROR - Not a drug candidate**

| Evidence Dimension | Score | Weight | Court Finding |
|-------------------|-------|--------|---------------|
| KG Signal | N/A | 15% | Score (99.95 percentile) reflects that serotonin is the MECHANISM of depression, not a treatment |
| Trial Safety | N/A | 20% | 15 terminated trials involve SSRIs/SNRIs, not exogenous serotonin administration |
| FAERS Signal | N/A | 25% | 2 reports (insufficient data) - expected because serotonin is not administered as a drug |
| Literature | N/A | 25% | No literature for serotonin repurposing; trials listed are ABOUT serotonin-modulating drugs |
| Molecular | N/A | 15% | Serotonin is an endogenous neurotransmitter; cannot be administered (poor BBB penetration, rapid MAO metabolism) |

**Court Finding:**
SEROTONIN is not a drug - it is an endogenous neurotransmitter. The database entry is a data artifact reflecting SSRI/SNRI trials, not exogenous serotonin administration. The knowledge graph confuses MECHANISM (serotonin dysfunction in depression) with TREATMENT (serotonin administration). This candidate should be REMOVED from consideration.

**Why This Matters:**
This category error reveals a fundamental limitation of knowledge graph embeddings: they cannot distinguish between "X is involved in disease Y" and "X treats disease Y." High KG scores for mechanistic targets (serotonin, dopamine) do not translate to viable drug candidates.

---

## Overall Assessment

### Drugs Recommended for Investigation
| Drug | Score | Strongest Signal | Biggest Risk | Next Step |
|------|-------|-----------------|--------------|-----------|
| BEFURALINE | 76 | Phase II efficacy (p=0.002), FDA Fast Track + Breakthrough Therapy | <300 patients, zero FAERS data, needs replication | Independent Phase II replication (N=200-300), 12-month safety follow-up |
| ROXINDOLE | 68 | Phase IIb efficacy (p=0.012), addresses anhedonia, FDA Fast Track | Modest effect size (d=0.45), D2 risks (impulse control), non-inferior not superior | Phase III superiority trial (N>500), impulse control monitoring (QUIP-RS) |

### Drugs Deprioritized
| Drug | Score | Primary Reason for Deprioritization |
|------|-------|-------------------------------------|
| BENZODIAZEPINE | 35 | No primary antidepressant evidence; GABAergic mechanism orthogonal to depression pathology |
| LITHIUM | 32 | FAERS risk signal (ROR=3.74, highest in dataset) contradicts KG prediction; already used adjunctively |
| SEROTONIN | N/A | Category error - endogenous neurotransmitter, not a drug candidate |

### Critical Findings

**1. Knowledge Graph Predictions Do Not Align with Real-World Safety Data**

The most important finding from this court is the **validation failure** of knowledge graph embeddings:

- BEFURALINE (KG percentile 100.0): Zero FAERS data (cannot assess)
- ROXINDOLE (KG percentile 99.98): Zero FAERS data (cannot assess)
- LITHIUM (KG percentile 99.91): FAERS ROR=3.74 (RISK signal, not protective)
- BENZODIAZEPINE (KG percentile 99.94): FAERS ROR=1.17 (neutral)
- SEROTONIN (KG percentile 99.95): Category error (not a drug)

Where FAERS data exists for other high-KG-scoring drugs, we observe the OPPOSITE of protection:
- ARIPIPRAZOLE: ROR=3.13 (213% increased depression, n=3952)
- PRAMIPEXOLE: ROR=2.56 (156% increased depression, n=558)
- MODAFINIL: ROR=2.74 (174% increased depressed mood, n=216)

**Interpretation:** Topological graph scores capture ASSOCIATION (co-mention in literature) but not CAUSALITY (therapeutic benefit). High KG percentiles indicate that a compound is frequently mentioned with a disease but do NOT predict clinical efficacy or safety. This is a critical tension that undermines the premise of knowledge-graph-driven repurposing.

**2. The "Dropped for Business Reasons" Narrative Requires Scrutiny**

- BEFURALINE: Zero depression trial history - this is NEW development, not repurposing
- ROXINDOLE: Failed in Parkinson's/schizophrenia (1990s), abandoned for 20+ years - historical failure context matters
- BENZODIAZEPINE: Never developed as primary antidepressant - not "dropped," never pursued
- LITHIUM: FDA-approved for bipolar disorder - not "dropped," still in use

Only BEFURALINE and ROXINDOLE represent genuine repurposing opportunities, and both require Phase III validation before investment.

**3. Absence of FAERS Data is a Risk Factor, Not a Green Light**

The advocate argued that "absence of FAERS data â‰  presence of harm." The court finds this argument MISLEADING:

- Regulatory agencies require POST-MARKETING surveillance for adverse events
- Absence of FAERS data means absence of real-world validation, not absence of risk
- Drugs with <1000 exposed patients are UNDERPOWERED to detect rare but serious adverse events (1-in-1000)
- Phase II trials for BEFURALINE (n=300) and ROXINDOLE (n=690) are too small for safety conclusions

**The burden of proof lies with those proposing the treatment.** Until Phase III data provides adequate safety surveillance, FAERS absence is a data gap, not evidence of safety.

**4. Phase II Data is Promising but Not Sufficient for Deployment**

Both BEFURALINE and ROXINDOLE have statistically significant Phase II efficacy:
- BEFURALINE: p=0.002, 45% response vs 22% placebo (strong effect)
- ROXINDOLE: p=0.012, 52% response vs 38% placebo, Cohen's d=0.45 (moderate effect)

However:
- Single Phase II results require independent replication before billion-dollar Phase III investment
- FDA Fast Track and Breakthrough Therapy designations are encouraging but not proof of efficacy
- Depression trials have high placebo response rates (30-40%) - replication is essential
- Real-world effectiveness may differ from controlled trial efficacy

### Methodology Notes

- All signals are HYPOTHESIS-GENERATING, not confirmatory
- Rescue Scores reflect convergent evidence strength, not clinical certainty
- Recommended next steps are Phase III clinical trials and wet-lab validation, not clinical deployment
- FAERS signals have known confounders:
  - **Confounding by indication:** Sicker patients receive experimental treatments
  - **Reporting bias:** Adverse events for new/controversial drugs are over-reported
  - **Healthy user bias:** Patients who tolerate a drug continue it; those who don't discontinue (survivorship bias)
- KG scores reflect graph topology (RotatE embeddings of literature co-mentions), not clinical causation
- Knowledge graphs cannot distinguish "X is mentioned with Y" from "X treats Y"

### Court's Confidence in Verdicts

| Verdict | Confidence | Reasoning |
|---------|-----------|-----------|
| BEFURALINE (76/100, PROMISING) | MODERATE (70%) | Phase II data is robust, but small sample size and lack of replication reduce confidence. FDA designations increase credibility if verified. |
| ROXINDOLE (68/100, PROMISING) | MODERATE (65%) | Phase IIb data is adequate, but modest effect size and historical failure in other indications temper optimism. Non-inferiority is insufficient justification. |
| BENZODIAZEPINE (35/100, DEPRIORITIZE) | HIGH (90%) | Clear lack of primary antidepressant evidence. GABAergic mechanism does not address monoamine pathology. Guidelines explicitly recommend against. |
| LITHIUM (32/100, DEPRIORITIZE) | HIGH (85%) | FAERS risk signal (ROR=3.74) is powerful skeptic evidence. Narrow therapeutic window and side effect profile make it unsuitable for unipolar MDD monotherapy. |
| SEROTONIN (N/A, DISQUALIFIED) | ABSOLUTE (100%) | Category error. Serotonin is not a drug. Database artifact. |

### Dissenting Notes

**Where the Court Disagreed with the Advocate:**

1. **On FAERS absence for BEFURALINE and ROXINDOLE:** The advocate argued absence of data is a "blank slate" and a strength. The court finds this argument misleading. Absence of data is a DATA GAP that limits safety assessment. Regulatory agencies require post-marketing surveillance; these drugs have none.

2. **On FDA Fast Track and Breakthrough Therapy designations:** The advocate cited these as validation of BEFURALINE's therapeutic promise. The court notes these designations are PRELIMINARY endorsements based on Phase II data and do NOT guarantee Phase III success. FDA designations require public database verification (not provided in evidence).

3. **On ROXINDOLE's "redemption story":** The advocate framed ROXINDOLE's revival as evidence that "the science caught up to the molecule." The court finds the 20-year hiatus concerning and notes that indication-specific failures (Parkinson's, schizophrenia) may reflect fundamental compound limitations, not just wrong indication.

**Where the Court Disagreed with the Skeptic:**

1. **On the value of Phase II data:** The skeptic characterized Phase II trials as "underpowered" and "requiring replication" to dismiss BEFURALINE's efficacy. The court finds the Phase II data (p=0.002, 45% vs 22% response) statistically robust and worthy of Phase III investment, pending replication.

2. **On the interpretation of zero depression trial history for BEFURALINE/ROXINDOLE:** The skeptic argued this is evidence the drugs were "never tested" and therefore not true repurposing candidates. The court finds this interpretation overly narrow - drugs can be repurposed even if never previously tested in the target indication, as long as preclinical/mechanistic rationale exists.

3. **On BENZODIAZEPINE's neutral FAERS signal:** The skeptic dismissed the neutral ROR=1.17 as "insufficient data." The court agrees the data is limited but notes that the broader benzodiazepine CLASS has extensive safety data on dependence/cognitive impairment that was not captured in the depression-specific analysis.

### Final Recommendation to Research Investors

**PURSUE Phase III Validation for BEFURALINE and ROXINDOLE:**
- Both candidates have statistically significant Phase II efficacy
- Both have multimodal mechanisms distinct from SSRIs
- Both address gaps in current treatment (rapid onset for BEFURALINE, anhedonia for ROXINDOLE)
- Investment contingent on:
  - Independent Phase II replication
  - Comprehensive drug-drug interaction studies
  - 12-month safety follow-up
  - FDA designation verification for BEFURALINE

**DO NOT PURSUE BENZODIAZEPINE, LITHIUM, or SEROTONIN:**
- BENZODIAZEPINE: No primary antidepressant evidence, GABAergic mechanism does not address core pathology
- LITHIUM: FAERS risk signal (ROR=3.74) contradicts repurposing hypothesis; already used adjunctively
- SEROTONIN: Category error - not a drug candidate

**Improve Knowledge Graph Methodology:**
- Knowledge graph predictions FAILED validation: high KG scores did not translate to protective FAERS signals
- Future iterations must distinguish mechanistic association from therapeutic causality
- Consider integrating negative trial results and FAERS risk signals into graph embeddings
- Validate graph predictions against external clinical endpoints before deploying at scale

---

**Verdict delivered by the DrugRescue Evidence Court on February 14, 2026.**

**These verdicts guide RESEARCH INVESTMENT decisions, not clinical practice. No drug discussed should be prescribed outside of controlled clinical trials.**
